| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jason L. Williams | Q27955522 |
| Thomas F. Gajewski | Q88137719 | ||
| P2093 | author name string | Stefani Spranger | |
| Brendan Horton | |||
| Leticia Corrales | |||
| Ayelet Sivan | |||
| P2860 | cites work | LAG-3, a novel lymphocyte activation gene closely related to CD4 | Q24300309 |
| Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway | Q24306635 | ||
| Prevention of allogeneic fetal rejection by tryptophan catabolism | Q24336018 | ||
| STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling | Q24336398 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Type I interferon response and innate immune sensing of cancer | Q27023235 | ||
| Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity | Q27489852 | ||
| Cyclic GMP-AMP Containing Mixed Phosphodiester Linkages Is An Endogenous High-Affinity Ligand for STING | Q27678540 | ||
| Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DMXAA | Q27679344 | ||
| Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 | ||
| Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells | Q28248489 | ||
| Type I interferon is selectively required by dendritic cells for immune rejection of tumors | Q28248500 | ||
| The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity | Q28304923 | ||
| Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. | Q40031362 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells | Q42581359 | ||
| Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy | Q44319954 | ||
| Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma | Q44443233 | ||
| Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma | Q44477273 | ||
| Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer | Q44915586 | ||
| Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance | Q47755230 | ||
| Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | Q50954469 | ||
| Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. | Q51023201 | ||
| Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites | Q56901877 | ||
| Immunomodulatory actions of xanthenone anticancer agents | Q79895771 | ||
| Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma | Q84906858 | ||
| Toll-like receptor control of the adaptive immune responses | Q29547305 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment | Q30415355 | ||
| Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors | Q30505678 | ||
| The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide | Q31144277 | ||
| Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment | Q33606150 | ||
| Effector memory T cells, early metastasis, and survival in colorectal cancer | Q33992461 | ||
| Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. | Q34153062 | ||
| Activated STING in a vascular and pulmonary syndrome | Q34241214 | ||
| Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid | Q34339243 | ||
| Intrinsic self-DNA triggers inflammatory disease dependent on STING. | Q34440680 | ||
| FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer | Q34755205 | ||
| Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation | Q35019491 | ||
| Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. | Q35050169 | ||
| STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. | Q35263440 | ||
| Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity | Q35634752 | ||
| Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints | Q36160526 | ||
| 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses | Q36380273 | ||
| IRF5 gene polymorphisms in melanoma | Q36380375 | ||
| Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo | Q36409007 | ||
| STING manifests self DNA-dependent inflammatory disease | Q36436812 | ||
| Molecular regulation of T-cell anergy | Q36466372 | ||
| Immune resistance orchestrated by the tumor microenvironment | Q36593747 | ||
| Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy | Q36823855 | ||
| Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment | Q36944380 | ||
| Inflammation-driven carcinogenesis is mediated through STING | Q37207341 | ||
| STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. | Q37502349 | ||
| Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes | Q37570109 | ||
| Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy | Q37778702 | ||
| Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms | Q38058493 | ||
| STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment | Q38949322 | ||
| Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha | Q39635625 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 19-31 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
| P1476 | title | Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment | |
| P478 | volume | 1036 |
| Q94526301 | A review of cancer immunotherapy: from the past, to the present, to the future |
| Q90677024 | Adaptive Immunity and the Tumor Microenvironment |
| Q90893993 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies |
| Q91736550 | Brain immunology and immunotherapy in brain tumours |
| Q97516973 | Cross-presentation of dead-cell-associated antigens by DNGR-1+ dendritic cells contributes to chronic allograft rejection in mice |
| Q60917194 | EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy |
| Q64227790 | HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles |
| Q60931630 | High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors |
| Q98665205 | Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies |
| Q91212056 | Interferons α and β in cancer: therapeutic opportunities from new insights |
| Q100416706 | Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer |
| Q90638466 | Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses |
| Q92334561 | Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer |
| Q92586096 | Making cold malignant pleural effusions hot: driving novel immunotherapies |
| Q90212537 | Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes |
| Q92880920 | Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies |
| Q64093111 | Proteoglycans and Immunobiology of Cancer-Therapeutic Implications |
| Q58087985 | Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again |
| Q91422883 | Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma |
| Q58119177 | Role of noninvasive molecular imaging in determining response |
| Q64971044 | STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. |
| Q90677051 | Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors |
| Q57138281 | Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy |
| Q99552010 | Trial watch: STING agonists in cancer therapy |
| Q90733181 | WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment |
| Q92136364 | Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies |
Search more.